Table 5.
Conditioning regimen related early toxicity by organ system within the first 30 days after allo-HCT.
| FBM (n = 136) | FTM (n = 105) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Organ | Grade 1 | Grade 2 | Grade 3/4 | Total | Grade 1 | Grade 2 | Grade 3/4 | Total | p value |
| Mucosa N (%) | 33 (24.3) | 18 (13.2) | 3 (2.2) | 54 (39.7) | 47 (44.8) | 15 (14.3) | 5 (4.8) | 67 (63.8) | 0.001 |
| Kidney N (%) | 49 (36.1) | 21 (15.4) | 11 (8.1) | 81 (59.5) | 37 (35.2) | 16 (15.2) | 21 (20.0) | 74 (70.5) | 0.08 |
| Liver N (%) | 39 (28.6) | 23 (16.9) | 4 (2.9) | 67 (49.3) | 32 (30.5) | 15 (14.3) | 7 (6.7) | 54 (51.4) | 0.74 |
| Others N (%) | 12 (8.8) | 14 (10.3) | 13 (9.5) | 39 (28.7) | 19 (18.1) | 11 (10.5) | 11 (10.5) | 42 (40.0) | 0.07 |
Data are number of patients (% of total). Toxicity effects and grades was assessed by Bearman’s criteria [40]. Other organs include bladder central nervous system, cardiac and lungs toxicity. Statistical analysis performed by Pearson’s chi square.
FBM fludarabine, BCNU/carmustine, melphalan, FTM fludarabine, thiotepa, melphalan.